Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients

British Journal of Cancer

Volumn 75, Issue 7, 1997, Pages 1049-1060

  De Bree, R ^a   Roos, J C ^a   Plaizier, M A B D ^a   Quak, J J ^a   Van Kamp, G J ^a   Den Hollander, W ^a   Snow, G B ^a   Van Dongen, G A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibody dependent cellular cytotoxicity; Biodistribution; Head and neck cancer; Human anti mouse antibody response; Monoclonal antibodies; Squamous cell carcinoma

Indexed keywords

CHIMERIC ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IODINE 125; IODINE 131; MONOCLONAL ANTIBODY; RHENIUM 186;

ADULT; AGED; ARTICLE; BLOOD; BONE MARROW; CANCER RECURRENCE; CELL MEDIATED CYTOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; MALE; MOUTH MUCOSA; MUSCLE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SKIN; SQUAMOUS CELL CARCINOMA;

EID: 0030903526     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.179     Document Type: Article

References (32)

1. Blumenthal RD, Fand I, Sharkey RM, Boerman OC, Kashi R and Goldenberg D (1991) The effect of antibody protein dose on the uniformity of tumor distribution of radio-antibodies: an autoradiographic study. Cancer Immunol Immunother 33: 351-358
2. Brakenhoff RH, Van Gog FB, Looney JE, Van Walsum M. Snow GB and Van Dongen GAMS (1995) Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer. Cancer Immunol Immunother 40: 191-200
3. Breitz HB, Weiden PL, Vanderheyden J-L, Appelbaum JW, Bjorn MJ, Fer MF, Wolf SB, Ratliff BA, Seiler CA, Foisie DC, Fisher DR, Schroff RW, Fritzberg AR and Abrams PG (1992) Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. J Nucl Med 33: 1099-1112
4. Buist MR, Kenemans P, Van Kamp GJ and Huisma HJ (1995a) Minor human antibody response to mouse and chimeric monoclonal antibodies after a single i.v. infusion in ovarian carcinoma patients: comparison of five assays. Cancer Immunol Immunother 40: 24-30
5. Buist MR, Kenemans P, Molthoff CFM, Roos JC, Den Hollander W, Brinkhuis M and Baak JPA (1995b) Tumor uptake of intravenously administered radiolabeled antibodies in ovarian cancer patients in relation to antigen expression and other tumor characteristics, Int J Cancer 64; 92-98
6. Crippa F, Bolis G, Seregni N, Gavoni N, Scarfone G, Ferraris C, Buraggi GL and Bombardieri E (1995) Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody 1-131 MOv18: clinical results in patients with minimal residual disease ot ovarian cancer. Eur, J Cancer 31 A: 686-690
7. De Bree R, Roos JC, Quak JJ, Den Hollander W. Snow GB and Van Dongen GAMS (1994a) Clinical screening of monoclonal antibodies 323/A3, cSF-25, and K928 for suitability of targeting tumors in the upper-aerodigestive and respiratory tract. Nucl Med Commun 15: 613-627
8. 2. J Nucl Med 35: 775-783
9. 2 in patients with head and neck cancer. Clin Cancer Res 1: 277-286
10. De Bree R, Roos JC, Quak JJ, Den Hollander W. Snow GB and Van Dongen GAMS (1995b) Radioimmunoscintigraphy and biodistribution of monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1: 591-598
11. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts. Cancer Res 53: 3524-3529
12. 186Re-labeled monoclonal antibody E48, Cell Biophys 24: 135-142
13. Goldenberg DM (1989) Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy. Semin Nucl Med 19: 332-339
14. Hermanek P and Sobin LH (eds) (1987) TNM Classification of Malignant Tumors, 4th edn. pp. 13-26. Springer Verlag: Berlin
15. Jacobs AL, Fer M, Su FM, Breitz H, Thompson J, Goodgold H, Cain J, Heaps J and Weiden P (1993) A phase-1 trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obsetet Gynecol 82: 586-593
16. Khazaeli MB, Conry R and Lobuglio AF (1994) Human immune response to monoclonal antibodies. J Immunother 15: 42-52
17. Oosterwijk E, Brander NH, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, Oettgen HF and Old LJ (1993) Antibody localization in human renal cell carcinoma: a phase 1 study of monoclonal antibody G250. J Clin Oncol 11: 738-750
18. Parker SL, Tong T, Holden S and Wingo PA (1996) Cancer statistics, 1996. C A Cancer J Clin 46: 5-27
19. Quak JJ, Van Dongen GAMS, Balm AJM, Brakkee JPG, Scheper RJ, Snow GB and Meijer CJLM (1990) A 22-kd surface antigen detected by monoclonal antibody E48 is exclusively expressed in stratified squamous and transitional epthelia. Am J Pathol 136: 191-197
20. Riethmuller G, Schncider-Gadicke E, Schlimok G, Schmiegel W, Hoftken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J and the German Cancer Aid 17-1A Study Group (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma. Lancet 343: 1177-1183
21. Schrijvers AHGJ, Quak JJ, Uyterlinde AM, Van Walsum M, Meijer CJLM, Snow GB and Van Dongen GAMS (1993) MAb U36. a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 53; 4383-4390
22. Siegel JA, Wessels BW, Watson EE, Stabin MG, Vriesendorp HM, Bradley EW, Badger CC, Brill B, Kwok CS, Stickney DR, Eckerman KF, Fisher DR, Bucbsbaum, DJ and Order SE (1990) Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconjug Radiopharm 3: 213-233
23. Stell PM and Rawson NSB (1990) Adjuvant chemotherapy in head and neck cancer. Br J Cancer 61: 779-787
24. Steplewski Z. Sun LK, Shearman CW, Ghrayeb J, Daddona P and Koprowski H (1988) Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 85: 4852-4856
25. Stupp R, Weichselbaum RR and Vokes EE (1994) Combined modality therapy of head and neck cancer. Semin Oncol 21: 349-358
26. Takahashi H, Wilson B, Ozturk M, Motte P, Strauss W, Isselbacher KJ and Wands JR (1988) In vivo localization of human colon adenocarcinoma by monoclonal antibody binding to a highly expressed cell surface antigen. Cancer Res 48: 6573-6579
27. Van Gog F, Visser GWM, Klok R, Van Der Schors R, Snow GB and Van Dongen GAMS (1996) Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate for clinical application: relationship between the number of chelated groups and biodistribution characteristics. J Nucl Med 37: 352-362
28. Van Hal NLW, Van Dongen GAMS, Rood-Knippels EMC, Van Der Valk P. Snow GB and Brakenhoff RH (1996) Monoclonal antibody U36, a suitable candidate for clinical immunotherapy. recognizes a CD44 isoform. Int J Cancer 60: 520-527
29. Vernham GA and Crowther JA (1994) Head and neck carcinoma - stage at presentation. Clin Otolaryngol 19: 120-124
30. Watson EE and Stabin M (1984) Basic alternatives software package for internal radiation dose calculations. In Computer Applications Health Physics, Kathren RL, Higby DP and McKinney MA (eds), Proc 17th Midyear Topical Symposium of the Heath Physics Society, pp. 4.49-4.58. Columbia Chapter, HPS, Richland: Washington.
31. Weber DA, Eckerman KF, Dillman LT and Ryman JC (eds) (1989) MIRD: radionuclide data and decay schemes. The Society of Nuclear Medicine Inc: New York
32. Wessels BW, Harisiadis L and Carabell SC (1989) Dosimetry and radiobiological efficacy of clinical radioimmunotherapy. J Nucl Med 30: 827